TRV
34
4
AEP
45
5
PH
60
5
MCO
67
3
MKC
54
3
T
32
2
BK
60
2
RL
73
5
ORLY
48
3
ADBE
50
3
CMS
57
2
PNW
55
3
DVA
62
5
NSC
33
6
EQR
33
6
DG
14
6
TAP
57
6
CVX
25
14
VNO
46
6
CSCO
63
5
TRV
34
4
AEP
45
5
PH
60
5
MCO
67
3
MKC
54
3
T
32
2
BK
60
2
RL
73
5
ORLY
48
3
ADBE
50
3
CMS
57
2
PNW
55
3
DVA
62
5
NSC
33
6
EQR
33
6
DG
14
6
TAP
57
6
CVX
25
14
VNO
46
6
CSCO
63
5
Financhill
Back

Theriva Biologics Quote, Financials, Valuation and Earnings

These 7 Stocks Will Be Magnificent in 2025

Get Your Copy of "These 7 Stocks Will Be Magnificent in 2025" Here.
Sell
27

TOVX
Theriva Biologics

Last Price:
$1.15
Seasonality Move:
27.37%

7 Day Trial

ALL ACCESS PASS

$ 7

Trump's Legacy-Defining Momentor Strike

But the Surprising Way Trump Solves it Could Cement His Legacy.

Theriva Biologics Price Quote

$1.15
+0.01 (+0%)
(Updated: December 21, 2024 at 6:40 PM ET)

Theriva Biologics Key Stats

Sell
27
Theriva Biologics (TOVX) is a Sell
Day range:
$1.14 - $1.19
52-week range:
$1.14 - $17.11
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.90
P/B ratio:
0.13%
Volume:
48.5K
Avg. volume:
130.7K
1-year change:
-91.69%
Market cap:
$3.2M
Revenue:
$0
EPS:
$-33.18

How Much Does Theriva Biologics Make?

Data Unavailable

Is Theriva Biologics Growing As A Company?

Data Unavailable

Theriva Biologics Stock Price Performance

  • Did Theriva Biologics Stock Go Up Last Month?
    Theriva Biologics share price went down by -9.52% last month
  • Did TOVX's Share Price Rise Over The Last Year?
    TOVX share price fell by -91.69% over the past 1 year

What Is Theriva Biologics 52-Week High & Low?

Theriva Biologics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Theriva Biologics?

Data Unavailable

Is Theriva Biologics Cash Flow Positive?

Data Unavailable

Theriva Biologics Return On Invested Capital

Data Unavailable

Theriva Biologics Earnings Date & Stock Price

Theriva Biologics Competitors

  • Who Are Theriva Biologics's Competitors?
    Below is a list of companies who compete with Theriva Biologics or are related in some way:
    • iBio Inc (IBIO)
    • Merck & Co Inc (MRK)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Pro-Dex Inc (PDEX)
    • Palatin Technologies Inc (PTN)

Theriva Biologics Dividend Yield

Data Unavailable

Theriva Biologics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -29.71%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 100.00
Upside from Last Price: 8671.93%

Major Shareholders

Data Unavailable